<DOC>
	<DOCNO>NCT00002202</DOCNO>
	<brief_summary>The purpose study see 141W94 safe effective indinavir use nucleoside reverse transcriptase inhibitor ( NRTIs ) 48 week . This study also examine effect drug body handle 141W94 .</brief_summary>
	<brief_title>A Comparison 141W94 Indinavir HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . HIV RNA &gt; = 400 copies/ml within 14 day prior randomize study drug administration . No active AIDSdefining opportunistic infection disease . Signed , inform consent parent legal guardian patient le 18 year age . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Unlikely complete randomize dosing period . Malabsorption syndrome gastrointestinal dysfunction might interfere drug absorption ability take oral medication . Serious medical condition ( e.g. , diabetes , cardiac dysfunction , hepatitis ) would compromise patient safety . Concurrent Medication : Excluded : Cytotoxic chemotherapeutic agent ( except local treatment Kaposi 's sarcoma ) . Investigational treatment ( treatment Treatment IND expandedaccess program evaluate individually ) . Immunomodulating agent systemic , highdose corticosteroid , interleukin , interferon . Terfenadine , astemizole , cisapride , triazolam , midazolam , ergotamine/dihydroergotaminecontaining regimen . Concurrent Treatment : Excluded : Radiation therapy ( except local treatment Kaposi 's sarcoma ) . Patients follow prior condition exclude : Clinically relevant pancreatitis hepatitis within last 6 month . Prior Medication : Excluded : Cytotoxic chemotherapeutic agent within 30 day study drug administration ( except local treatment Kaposi 's sarcoma ) . Protease inhibitor therapy . Dose vaccine investigational HIV vaccine trial within 3 month prior study drug administration . Immunomodulating agent systemic , highdose corticosteroid , interleukin , interferon within 30 day study drug administration . Prior Treatment : Excluded : Radiation therapy within 30 day prior study drug administration ( except local treatment Kaposi 's sarcoma ) . Risk Behavior : Excluded : Current alcohol illicit drug use may interfere drug absorption ability take oral medication . Required : NRTI therapy day entry screen . Required : &gt; = 12 week NRTI therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>VX 478</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>